Trials / Completed
CompletedNCT02726009
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 230 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring androgen deprivation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2020-05-15
- Completion
- 2020-05-15
- First posted
- 2016-04-01
- Last updated
- 2021-12-15
Locations
19 sites across 1 country: India
Source: ClinicalTrials.gov record NCT02726009. Inclusion in this directory is not an endorsement.